The Life Sciences (LS) industry has been at the forefront of the COVID-19 response, from carrying out drug trials and vaccine development to producing Personal Protective Equipment (PPE) and ventilators. The industry was already growing significantly in digital technologies adoption and has been further pushed by the pandemic to adopt new and disruptive technologies to ensure business continuity. There is a historic surge in investment in digital services such as cybersecurity, cloud migration, virtual engagement models for clinical trials and sales and marketing, and AI/ML for drug discovery. Digital transformation has become a strategic imperative for LS enterprises in a post-COVID-19 world, and they are looking for thought leaders and strategic partners that can help them on their transformation journeys.
To support enterprises on their digital journeys, service providers are ramping up capabilities, by building industry-specific tools and accelerators and engaging in life sciences-specific partnerships and co-innovation initiatives. Everest Group’s Life Sciences ITS research program analyzes service provider capabilities and their impact on the life sciences digital services market. In this report, we analyze 27 IT service providers’ digital capabilities specific to the life sciences sector. Our assessment is based on Everest Group’s annual RFI process for the calendar year 2020, interactions with leading digital service providers, client reference checks, and an in-depth analysis of the digital services market.
This report comprises three sections, each containing insights about the life sciences digital service providers’ landscape, as outlined below: